Where does CVRx, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), CVRx, Inc. ranks #13,936 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does CVRx, Inc. hold?

CVRx, Inc. holds 21 US utility patents granted between 2015 and 2024, spanning 6 technology areas.

What is CVRx, Inc.'s Innovation Score?

CVRx, Inc. has an Innovation Score of 44.1 out of 100 (top 26% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does CVRx, Inc. focus on?

CVRx, Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 16 patents, ranking #233 of 1,943 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is CVRx, Inc.'s patent grant rate increasing or decreasing?

CVRx, Inc.'s recent grant velocity is -9% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for CVRx, Inc.'s patents?

CVRx, Inc.'s patents average 11.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the CVRx, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

CVRx, Inc.

USPTO PatentsView assignee record - 21 granted patents across 6 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cvrx ranks #13,936 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 6 technology areas.

#13,936
of 49,997 US assignees by volume: Top 26%
by Innovation Score (44.1/100): 11.7
avg claims per patent: -9%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13936 · US Corporation #13,936 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-PAR · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-SMALL 21 grants
MID-PACK #13,936/49,997
PHOTO-FINISH Cana Technology
CPC-NARROW A61N · 6 areas
INNOV-PAR 44.1/100
CLAIMS-PAR 11.7 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT -9% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cana Technology, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cvrx’s 44.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.7 pts (24%) Velocity 17.8 pts (40%) Breadth 8.7 pts (20%) Claim depth 7.0 pts (16%)

Qualcomm Incorporated · highest

85
CVRx · this assignee

44
3D Lighting… · lowest

7

What this shows Cvrx's Innovation Score is 44.1/100 (top 26% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cvrx?

Each dot is one of Cvrx’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cvrx’s own 11.7 claims/patent is at or below the 15.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Cvrx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cvrx's grants concentrate

CVRx, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 76.2% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2015 (5 grants) versus a trough of 1 in 2019. By volume, Cvrx sits between Collibra Belgium BV and Carleton Life Support Systems Inc..

Cvrx's three-year grant acceleration

CVRx, Inc. shows 8 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Collibra Belgium…

21
Conextions

21
Continuus Materia…

21
Cqms PTY

21
Cana Technology

21
Carbon Holdings I…

21
Carefusion

21
Carleton Life Sup…

21
Cvrx ◀

21

What this shows CVRx holds 21 patents at rank #13,916, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near CVRx

By rank, the assignees closest to #13,916 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in CVRx's primary technology class.

Cvrx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 26% higher than 74% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

CVRx, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	23.8%
2016	5	23.8%
2019	1	4.8%
2020	1	4.8%
2021	1	4.8%
2022	1	4.8%
2023	5	23.8%
2024	2	9.5%

Which technologies does CVRx, Inc. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 16

A61B - DIAGNOSIS; SURGERY; Identification 4

F05D - Indexing Scheme FOR Aspects Relating TO Non-positive-displacement Machines OR Engines, Gas-turbines OR Jet-propulsion Plants 1

F02C - Gas-turbine PLANTS; AIR Intakes FOR Jet-propulsion PLANTS; Controlling Fuel Supply IN Air-breathing Jet-propulsion Plants 1

F01K - Steam Engine PLANTS; Steam ACCUMULATORS; Engine Plants NOT Otherwise Provided FOR; Engines Using Special Working Fluids OR Cycles 1

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

CVRx, Inc.'s patent record in context - here's where to go next.

CVRx, Inc.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 76.2% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #13,936 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare CVRx, Inc. against Collibra Belgium BV, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.